Affordable Access

deepdyve-link
Publisher Website

Complete remission for 4 years with crizotinib in advanced ALK-positive non-small cell lung cancer after thoracostomy for empyema.

Authors
  • Van Damme, Eufra1
  • Kiselinova, Maja2
  • Van Schoote, Elke3
  • 1 Faculty of Medicine, University of Ghent, Ghent, Belgium. , (Belgium)
  • 2 Department of Internal Medicine, University of Ghent, Ghent, Belgium. , (Belgium)
  • 3 Department of Pneumology, Sint-Elisabeth Hospital, Zottegem, Belgium. , (Belgium)
Type
Published Article
Journal
Tumori Journal
Publisher
SAGE Publications
Publication Date
Dec 01, 2019
Volume
105
Issue
6
Identifiers
DOI: 10.1177/0300891619845481
PMID: 31023173
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

Anaplastic lymphoma kinase (ALK) gene translocation occurs in 3%-5% of patients with non-small cell lung cancer (NSCLC), typically in younger patients. Crizotinib (tyrosine kinase inhibitor) has been considered as the standard of care for advanced ALK-positive lung cancer but it only gives a median progression-free survival of 7.7-11 months. A 41-year-old old man, former smoker, was diagnosed with NSCLC in the right lung with manifest pleural effusion. This case was complicated by a pleural empyema and because of a trapped lung, there was an indication for the construction of a thoracostomy. After confirmation of the ALK translocation, therapy with crizotinib was started. After 8 weeks, there was excellent response, and 6 months later, all lesions were undetectable on CT scan. There was also complete healing of the thoracostomy wound. This case describes a relatively young patient with a poor prognosis but with a remarkable and long-term response to crizotinib monotherapy.

Report this publication

Statistics

Seen <100 times